{"groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received intravenous (IV) infusion of 2.5 milligram (mg)/kilogram (kg) belantamab mafodotin on Day 1 of Cycle 1 and 1.9 mg/kg on Day 1 of Cycle 2 onwards in each 28-day cycle, in combination with oral 4 mg per day Pomalidomide capsule on Days 1 to 21 of each 28-day cycle; and oral 40 mg per day Dexamethasone tablet on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, initiation of another anti-myeloma therapy or end of study, whichever occurs first.","id":"FG000","title":"Belantamab Mafodotin+Pomalidomide+Dexamethasone"},{"description":"Participants with RRMM received oral 4 mg per day Pomalidomide capsule on Days 1 to 14 of each 21-day cycle, in combination with subcutaneous (SC) injection of 1.3 mg/meter\\^2(m\\^2) Bortezomib on Days 1, 4, 8, 11, of each 21-day cycle for Cycles 1 through 8, and on Days 1, 8, of each 21-day cycle for Cycles 9+, and oral 20 mg Dexamethasone tablet on Days 1, 2, 4, 5, 8, 9, 11, 12, of each 21-day cycle for Cycles 1 through 8 and then on Days 1, 2, 8, 9, every 3 Weeks (Q3W) from Cycles 9 onwards until disease progression, death, unacceptable toxicity, withdrawal of consent, initiation of another anti-myeloma therapy or end of study, whichever occurs first.","id":"FG001","title":"Pomalidomide+Bortezomib+Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Protocol Deviation"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"8"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"94"},{"groupId":"FG001","numSubjects":"84"}],"type":"Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"155"},{"groupId":"FG001","numSubjects":"147"}],"comment":"Intent-to-Treat (ITT) Population included of all randomized participants whether or not randomized treatment was administered.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"150"},{"groupId":"FG001","numSubjects":"145"}],"comment":"All randomized participants who received at least 1 dose of study intervention (any component).","type":"Safety Population"},{"achievements":[{"comment":"Note: Participants who died following randomization whilst on study, including 1 participant who died prior to dosing.","groupId":"FG000","numSubjects":"48"},{"comment":"Note: Participants who died following randomization whilst on study, including 1 participant who died prior to dosing.","groupId":"FG001","numSubjects":"54"}],"comment":"Note: Participants who died following randomization whilst on study, were considered to have completed the study.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"107"},{"groupId":"FG001","numSubjects":"93"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The results presented are until the primary completion date. Additional results will be provided within a year of study completion."}